Drug updated on 9/4/2024
| Dosage Form | Injection (subcutaneous; 25 mg/0.5 mL) |
| Drug Class | Transthyretin-directed small interfering RNA |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Latest News
Summary
- Amvuttra (vutrisiran) is indicated for the treatment of polyneuropathy due to hereditary transthyretin-mediated amyloidosis in adults.
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Neuropathy Impairment Score-Lower Limbs (NIS-LL): Vutrisiran resulted in a statistically significant improvement in polyneuropathy with a relative mean change of -5.3 (95% CI: -9.4, -1.2; p = 0.011) compared to tafamidis.
- Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) score: Vutrisiran significantly improved health-related quality of life with a relative mean change of -18.3 (95% CI: -28.6, -8.0; p < 0.001) compared to tafamidis.
- Nutritional Status (modified Body Mass Index, mBMI): Vutrisiran showed superior outcomes in nutritional status with a relative mean change of 63.9 (95% CI: 10.1, 117.7; p = 0.020) compared to tafamidis.
- There is no safety information available in the reviewed studies.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Amvuttra (vutrisiran) Prescribing Information. | 2022 | Alnylam Pharmaceuticals Inc., Cambridge, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy | 2023 | Expert Opinion on Pharmacotherapy |